Kalbe Genexine Biologics
- Biotech or pharma, therapeutic R&D
- CMO, CRO
PT Kalbe Genexine Biologics (KGbio) is a leading biopharmaceutical company, who is focusing in co-development and commercializing biologics in worldwide except US and Japan.
In BIO 2025, we are focusing to license out Ready-to-launch assets, Serplulimab (anti PD 1) - Zerpidio® and Efepoetin Alpha (long acting EPO)- Efesa®.
We are also open to licensing-in late stage asset in Oncology, Diabetes and Autoimmune area.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}